A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice (Q40168564)

18 September 2017

A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice (English)

1 reference

18 September 2017

0 references

7

Sukathida Ubol

1 reference

18 September 2017

5

Richard G Jarman

1 reference

18 September 2017

Butsaya Thaisomboonsuk

4

object named as

Butsaya Thaisomboonsuk

1 reference

18 September 2017

Taweewun Hunsawong

1

1 reference

18 September 2017

Panya Sunintaboon

2

1 reference

18 September 2017

Saradee Warit

3

1 reference

18 September 2017

In-Kyu Yoon

6

1 reference

18 September 2017

Stefan Fernandez

8

1 reference

18 September 2017

language of work or name

English

0 references

publication date

18 February 2015

1 reference

18 September 2017

1 reference

18 September 2017

33

1 reference

18 September 2017

14

1 reference

18 September 2017

1702-1710

1 reference

The global distribution and burden of dengue

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Patchiness and co-existence of indigenous and invasive mussels at small spatial scales: the interaction of facilitation and competition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Development of Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Effects of formalin inactivation on bovine herpes virus-1 glycoproteins and antibody response elicited by formalin-inactivated vaccines in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

An emerging HIV risk environment: a preliminary epidemiological profile of an MSM POZ Party in New York City.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

PMMA-N,N,N-trimethyl chitosan nanoparticles for fabrication of antibacterial natural rubber latex gloves.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Bacillus Calmette-Gu�rin shares with virulent the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Chitosan-based nanoparticles for improving immunization against hepatitis B infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Effects of stimulated or immunologically activated macrophages on the induction of immune responses to Listeria monocytogenes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

The effect of various inflammatory agents on the phagocytosis and cytokine profile of mouse and rat macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Synthesis of poly(methyl methacrylate) core/chitosan-mixed-polyethyleneimine shell nanoparticles and their antibacterial property

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: enhanced uptake by and immunostimulatory activity of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Evidence for active antigen presentation by monocyte/macrophages in response to stimulation with particles: the expression of NFκB transcription factors and costimulatory molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Tumor necrosis factor-alpha, transforming growth factor-β1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

RNA sensors enable human mast cell anti-viral chemokine production and IFN-mediated protection in response to antibody-enhanced dengue virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Dengue virus selectively induces human mast cell chemokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

T-cell immunity to infection with dengue virus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.016

10.1016/J.VACCINE.2015.02.016

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference